About Impax
  • Company Profile
  • History
  • Vision and Values
  • Executive Team
  • Board of Directors
  • Business Development
  • Locations
Products
  • Generic Products
    • Product Listings
    • Product Packaging Information
    • Generic Trade Relations
    • Generic Product Contacts
  • Specialty Products
    • Specialty Trade Relations
    • Specialty Product Contact
  • Corporate Drug Safety
    • Adverse Event Reporting
    • Product Complaint Reporting
    • Medical Inquiries
    • Quality
Careers
  • Benefits of Joining Our Team
Corporate Responsibility
  • Patient Resources
  • Compliance and Ehitcs
  • Code of Conduct
Research
  • Generics Division
  • Specialty Pharma Division
    • Clinical Activities
    • Parkinson’s Disease
News
  • Press Releases
Contact
Skip to main content
Impax
  • Home
Menu Menu
Visit Product Sites
  • Albaneza
  • Emverm
  • Epinephrine Auto-Injector
  • Rytary
  • Zomig
  • Investor Relations
  • SEC Filings
Home
About Impax
  • About Impax
  • Company Profile
  • History
  • Vision and Values
  • Executive Team
  • Board of Directors
  • Business Development
  • Locations
Corporate Responsibility
    Corporate Responsibility
  • Patient Resources
  • Compliance and Ehitcs
  • Code of Conduct
Products
  • Products
  • Generic Products
    • Product Listings
    • Product Packaging Information
    • Generic Trade Relations
    • Generic Product Contacts
  • Specialty Products
    • Specialty Trade Relations
    • Specialty Product Contact
  • Corporate Drug Safety
    • Adverse Event Reporting
    • Product Complaint Reporting
    • Medical Inquiries
    • Quality
Research
  • Research
  • Generics Division
  • Specialty Pharma Division
    • Clinical Activities
    • Parkinson’s Disease
Investor Relations
News
  • Press Releases
Careers
  • Benefits of Joining Our Team
Contact
Home Home/News/Press Releases
Home Home  >  News  >  Press Releases
  • Investor Relations
  • SEC Filings
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Nov 25, 2015
Impax Receives European Commission Marketing Authorization for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's Disease
PDF format download (opens in new window)
Nov 24, 2015
Impax Launches Generic Version of Avodart® (Dutasteride) Capsules, 0.5 mg
PDF format download (opens in new window)
Nov 09, 2015
Impax Reports Third Quarter 2015 Financial Results
PDF format download (opens in new window)
Nov 05, 2015
Impax to Present at the 24th Annual Credit Suisse Healthcare Conference
PDF format download (opens in new window)
Oct 21, 2015
Impax Receives FDA Approval for Generic Version of Intuniv® (Guanfacine) Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg
PDF format download (opens in new window)
Oct 09, 2015
Impax to Report Third Quarter 2015 Results on November 9, 2015
PDF format download (opens in new window)
Oct 08, 2015
Janet S. Vergis Appointed to Impax Laboratories Board of Directors
PDF format download (opens in new window)
Oct 05, 2015
Impax Receives FDA Approval for Generic Version of DIABETA® (Glyburide) Tablets, USP, 1.25 mg, 2.5 mg, and 5 mg
PDF format download (opens in new window)
Sep 25, 2015
Impax Receives Positive CHMP Opinion for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's disease
PDF format download (opens in new window)
Sep 22, 2015
Impax Receives FDA Approval for Generic Version of Testred® C-III (Methyltestosterone Capsules, USP), 10 mg
PDF format download (opens in new window)
Sep 17, 2015
Impax Receives FDA Approval for Generic Version of Mestinon® Timespan® Tablets, 180 mg
PDF format download (opens in new window)
Sep 11, 2015
Impax to Present at the Morgan Stanley Global Healthcare Conference
PDF format download (opens in new window)
Sep 08, 2015
Impax Announces Resolution of FDA Warning Letter Related to its Hayward Manufacturing Facility
PDF format download (opens in new window)
Aug 10, 2015
Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG
PDF format download (opens in new window)
Aug 10, 2015
Impax Reports Second Quarter 2015 Financial Results
PDF format download (opens in new window)
Jul 06, 2015
Impax to Report Second Quarter 2015 Results on August 10, 2015
PDF format download (opens in new window)
Jul 06, 2015
Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors
PDF format download (opens in new window)
Jun 25, 2015
Impax Laboratories, Inc. Prices Private Offering of Convertible Senior Notes
PDF format download (opens in new window)
Jun 24, 2015
Impax Laboratories, Inc. Announces Private Offering of Convertible Senior Notes
PDF format download (opens in new window)
Jun 16, 2015
FDA Approves ZOMIG® (zolmitriptan) Nasal Spray for Migraine in Pediatric Patients (Ages 12-17)
PDF format download (opens in new window)
Jun 04, 2015
Impax to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
May 14, 2015
Impax to Present at the UBS 2015 Global Healthcare Conference
May 11, 2015
FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility
May 11, 2015
Impax Reports First Quarter 2015 Financial Results
May 08, 2015
Impax to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
May 04, 2015
Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance
Apr 16, 2015
Impax to Report First Quarter 2015 Results on May 11, 2015
Mar 10, 2015
Impax Completes Acquisition Of Tower Holdings, Inc. And Lineage Therapeutics Inc.
Feb 25, 2015
Impax to Present at the Cowen and Company 35th Annual Health Care Conference
Feb 24, 2015
Impax Revenues Increased 30% to $131 Million in Fourth Quarter 2014
Jan 29, 2015
Impax to Report Fourth Quarter 2014 Results on February 24, 2015
Jan 26, 2015
Impax Receives FDA Approval for a Generic Version of Lamictal® Orally Disintegrating Tablets (ODT)
Jan 08, 2015
Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease
Jan 06, 2015
Impax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
Impax
  • About Impax
  • Corporate Responsibility
  • Products
  • Research
  • Investor Relations
  • News
  • Contact
  • SiteMap |
  • Privacy Statement |
  • Legal Notices |
  • Terms & Conditions
© Impax Laboratories, LLC
Powered By Q4 Inc. 5.15.0.14 (opens in new window)